Identification of the first synthetic allosteric modulator of the CB2receptors and evidence of its efficacy for neuropathic pain relief by Gado, Francesca et al.
Identification of the first synthetic allosteric 
modulator of the CB2 receptors and evidence of its 
efficacy for neuropathic pain relief 
Francesca Gado,⊥,# Lorenzo Di Cesare Mannelli,§, # Elena Lucarini,§ Simone Bertini,⊥ Elena 
Cappelli,⊥ Maria Digiacomo,⊥ Lesley A Stevenson,ψ Marco Macchia,⊥ Tiziano Tuccinardi,⊥,† 
Carla Ghelardini,§ Roger G. Pertwee,ψ Clementina Manera⊥,* 
⊥Department of Pharmacy, University of Pisa, 56126 Pisa. §Department of Neuroscience, 
Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University 
of Florence, 50139 Florence, Italy. ψSchool of Medicine, Medical Sciences and Nutrition, Institute 
of Medical Sciences, University of Aberdeen, AB25 2ZD Aberdeen, Scotland, UK. †Sbarro Institute 
for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and 
Technology, Temple University, Philadelphia, Pennsylvania 19122, United States. 
 
  
Abstract  
 
The direct activation of cannabinoid receptors (CBRs) results in several beneficial effects, therefore 
several CBRs ligands have been synthesized and tested in vitro and in vivo. However none of them 
reached an advanced phase of clinical development due mainly to side effects on the CNS. Medicinal 
chemistry approaches are now engaged to develop allosteric modulators that might offer a novel 
therapeutic approach to achieve potential therapeutic benefits avoiding inherent side effects of 
orthosteric ligands. Here we identify the first ever synthetized positive allosteric modulator (PAM) 
that targets CB2Rs. The evidence for this was obtained using [
3H]CP55940 and [35S]GTPγS binding 
assays. This finding will be useful for the characterization of allosteric binding site(s) on CB2Rs 
which will be essential for the further development of CB2R allosteric modulators. Moreover, the 
new CB2R PAM displayed antinociceptive activity in vivo in an experimental mouse model of 
neuropathic pain, raising the possibility that it might be a good candidate for clinical development. 
 
 
  
Introduction 
The endocannabinoid system (ECS) is a ubiquitous neuromodulatory system with wide-ranging 
actions.1 Cannabinoid receptors (CB1Rs, CB2Rs) are members of G-protein-coupled receptors family. 
Several findings indicate that CB2R ligands, which do not share the ability of CB1R agonists to 
produce psychotropic effects or of selective CB1R antagonists to produce other serious adverse 
effects,2-4 appear to be promising drugs for treating several diseases.5-7 Medicinal chemistry 
approaches are now being adopted to develop more efficacious agonists, and in particular, to 
investigate the possibility of developing allosteric modulators (Figure 1) that might offer a novel 
therapeutic approach with minimal side-effects. It has been reported that CBRs have spatially distinct 
allosteric sites that can be targeted by exogenous/endogenous substances modulating the receptors’ 
functional state.8-15 Allosteric modulators offer numerous advantages respect to orthosteric ligands, 
such as a greater subtype selectivity for the higher sequence divergence at allosteric sites, than the 
orthosteric domains; furthermore, allosteric modulators possess tissue selectivity because they exert 
effects only where endocannabinoids are present and eventually they might provide synergizing 
effects with other co-administered ECS modulators.16-19 Moreover, they could have the advantage of 
activating or inhibiting the biased signaling properties of these GPCRs. For these reasons, allosteric 
modulators might represent a valid alternative method to modulate the ECS and they could be useful 
for the development of future drugs. They are classified in: positive allosteric modulators (PAMs), 
negative allosteric modulators (NAMs) which activate or inhibit the receptor response, respectively, 
neutral or silent allosteric modulators, which do bind to the allosteric site without affecting the 
response of the endogenous agonist and bitopic ligands that bind to both the orthosteric and allosteric 
sites. 
 Figure 1. General classification of allosteric modulators: PAMs, NAMs and SAMs. 
 
To date, few allosteric modulators for CB1Rs have been developed. Among them, indole 
derivatives,9,20 urea derivatives21 and certain other molecules have a PAM profile (Figure 2).22 Up to 
now, the only CB2R allosteric modulator reported in the literature is the endogenous Pepcan-12 
(Figure 2) which was reported also to be a CB1R NAM.
23 
 
 
Figure 2. Representative CBRs allosteric modulators. 
 
 
In this work, we present evidence that the novel synthetic compound C2 (Figure 3), is a positive 
allosteric modulator (PAM) of the CB2Rs. This evidence was obtained by carrying out [
3H]CP55940 
and [35S]GTPγS binding assays. C2 is a member of a group of compounds that were obtained by 
modifying the structure of 2-oxopyridine-3-carboxamides derivatives of general structure A and B 
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(Figure 3) that had been previously shown to be orthosteric CBR ligands.24 With the aim of deeply 
exploring the structure-activity relationships of derivatives A and B, we synthesized derivatives C1-
C5, D1-D6 and E1 in which the amide group in position C-3 of the 2-oxopyridine-3-carboxamides 
A and B was substituted with the corresponding retro-amide (Figure 3). The substituents of 
derivatives C and D have been selected on the basis of the best results achieved with the series A and 
B. Moreover, compound E1, characterized by an OH group in position 4, has been synthesized, to 
understand the role of the methyl group and, at the same time, to define the effect on the affinity of 
binding to CBRs of a polar group in the same position (Figure 3). Finally, derivative C2 displayed 
antinociceptive activity in vivo in an experimental mouse model of neuropathic pain. 
 
 
Figure 3. Design of retro-amides C1-C5, D1-D6 and E1. 
 
Results and Discussion 
Chemistry. The synthesis of 2-oxopyridines C, D and E1 was obtained as reported in Schemes 1-
3.  
The cycloheptanecarboxamide derivatives C1-C5 were synthesized (Scheme 1) starting from the 
2-hydroxy-4-methyl-3-nitropyridine which underwent a catalytic hydrogenation to afford derivative 
1. The reaction between the amine 1 and the cycloheptanecarbonyl chloride in toluene, DMF and 
triethylamine, carried out initially at 0 °C and then at 30 °C for 48 hours, afforded the amide 2. The 
acyl chloride was prepared from reaction between cycloheptanecarboxylic acid with SOCl2 at 76 °C 
for 3 hours. The derivative 2 was reacted with CsF and then with p-fluorobenzyl chloride, yielding 
the desired N-alkylated compound C1. The derivatives C2-C5 were synthesized starting from the 
amide 2 which was treated with a solution of bromine in CHCl3, affording the corresponding 5-bromo 
derivative 3. The treatment of 3 with p-fluorobenzyl chloride via a similar method to that used for the 
preparation of C1, afforded the desired N-alkylated compound C2 (Scheme 1). The 5-aryl derivatives 
C3 and C4 were yielded starting from the 5-bromo derivative C2 via a Suzuki-Miyaura cross-
coupling reaction with the suitable boronic acids in dry toluene and Pd(PPh3)4 as catalyst (Scheme 
1). The 5-chloro derivative C5 was obtained from amide 2 which was treated with N-
chlorosuccinimide to give compound 4. The N-alkylation of 4, carried out following the same method 
used to yield C1-C4, afforded the desired compound C5 (Scheme 1). 
As reported in Scheme 2, the compounds D1-D6 were obtained starting from 2-hydroxy-6-methyl-
3-nitropyridine which underwent a catalytic hydrogenation, using Pd/C as catalyst, to afford 
compound 5. Subsequently, the condensation of 5 with cycloheptanecarboxylic acid using TBTU as 
condensing reagent in the presence of triethlylamine, yielded the carboxamide 6 which, for N-
alkylation with NaH, LiBr and p-fluoro-benzylchloride, gave D1. The reaction of 6 with a solution 
of bromine in CHCl3 produced the corresponding 5-bromo derivative 7 which was N-alkylated by the 
same procedure previously described, to yield the desired compound D2. The derivatives D3 and D4 
were obtained from D2 by Suzuki cross-coupling reaction with the suitable arylboronic acid (Scheme 
2). The reaction of compound 6 with N-chlorosuccinimide in acetonitrile at reflux gave the 5-chloro 
derivative 8 which was N-alkylated using the procedure already described, to afford compound D5 
(Scheme 2). The carboxamide 6 was also treated with 1-chloromethyl-4-fluoro-1,4-
diazoniabicyclo[2.2.2] octanebis(tetrafluoroborate) in acetonitrile at reflux for 12 hours, yielding the 
5-fluorinated derivative 9 which was N-alkylated to afford the desired compound D6 (Scheme 2).  
 
Scheme 1. Synthesis of compounds C1-C5 
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Reagents and conditions: (i) H2, Pd/C, MeOH, rt, 12 h; (ii) 1) cycloheptancarboxylic acid, SOCl2, 
76 °C, 3 h; 2) acyl chloride, toluene, DMF, NEt3, 0-32 °C, 48 h; (iii) 1) DMF, CsF, rt, 1 h; 2) p-
fluorobenzyl chloride, 50 °C, 12 h; (iv) Br2, CHCl3, 30 °C, 12 h; (v) triphenylphosphine, Pd(OAc)2, 
K2CO3, suitable arylboronic acid, 110 °C, 12 h; (vi) N-chlorosuccinimide, ACN, reflux, 12 h. 
 
 
 
 
 
 
Scheme 2. Synthetic pathway for compounds D1-D6 
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Reagents and conditions: (i) H2, Pd/C, MeOH, rt, 12 h; (ii) cycloheptancarboxylic acid, TBTU, 
NEt3, DMF, 0 °C rt, overnight; (iii) NaH 60%, LiBr, p-fluorobenzyl chloride, DMF, DME, 65 °C, 12 
h; (iv) Br2, CHCl3, rt, 12 h; (v) triphenylphosphine, Pd(OAc)2, K2CO3, suitable arylboronic acid, 
110 °C, overnight; (vi) N-chlorosuccinimide, ACN, reflux, 12 h; (vii) 1-chloromethyl-4-fluoro-1,4-
diazoniabicyclo[2.2.2] octanebis(tetrafluoroborate), ACN, reflux, 12 h. 
 
Finally, compound E1 was synthesized as reported in Scheme 3, starting from 4-hydroxy-3-nitro-
2-oxo-1,2-dihydropyridine which underwent a catalytic hydrogenation to yield derivative 10. 
Reaction of 10 with cycloheptanecarbonyl chloride prepared as reported above, gave compound 11 
which, by treatment with a solution of bromine in CHCl3, yielded compound 12. The N-alkylation of 
12 carried out with CsF and p-fluorobenzyl chloride, afforded the derivative E1. 
Scheme 3. Synthetic pathway for compound E1 
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Reagents and conditions: (i) H2, Pd/C, MeOH, rt, 12 h; (ii) 1) cycloheptancarboxilic acid, SOCl2, 
76 °C, 3 h; 2) Toluene, DMF, NEt3, 0-32 °C, 48 h; (iii) Br2, CHCl3, 30 °C, 12 h; (iv) 1) DMF, CsF, 
rt, 1 h; 2) p-fluorobenzylchloride, 50 °C, 12 h. 
 
[3H]CP55940 Binding Assays. Compounds C1-C5, D1-D6 and E1 were evaluated for CBRs 
binding by incubating these compounds with membrane preparations obtained from Chinese hamster 
ovary (CHO) cells overexpressing hCB1Rs or hCB2Rs in the presence of 0.7 nM [
3H]CP55940, a 
high-affinity orthosteric CB1R and CB2R radioligand. Also, the N1-unsubsituted analogue of C2, 
derivative 3, was assayed with the aim of exploring the influence of the substituent in position 1. 
Regarding the CB1Rs, initially, all compounds were screened at 100 nM. The results (Figure S1 
in Supporting Information) showed that only compounds C1, D1, D5 and derivative 3 displaced 
[3H]CP55940. Rather unexpectedly, all the other compounds enhanced the binding of the radioligand 
to CB1Rs. In particular, compounds C2, C3 and D3 were found to be effective as enhancers at 100 
nM (Figure S1 in Supporting Information) and their concentration-dependent (1 nM to 1 µM) CB1R 
binding curves (C3 and D3 Figure S2 in Supporting Information) indicated compound C2 (Figure 4) 
to be the best enhancer, inducing approximately a 40% increase in the binding of [3H]CP55940 up to 
a concentration of 1 µM. However, no increase in such binding was induced by C2 at 10 µM. These 
data suggest that C2 may be a CB1R PAM (Figure 4).  
In the case of the CB2Rs, concentration-dependent binding curves (Figure S3 in Supporting 
Information) indicate that D1-D6, C1, C3-C5 and 3 were either weak orthosteric ligands or 
completely inactive. Derivative E1 was found to enhance weakly the binding of [3H]CP55940 (Figure 
S3 in Supporting information), whereas compound C2 strongly increased the binding of 
[3H]CP55940 at very low concentrations (Figure 4) raising the possibility that it may be a CB2R 
PAM. 
 
Figure 4. Effects of compounds C2 (at 1 nM to 10 µM) on [3H]CP55940 binding to CB1R (left) 
and CB2R (right). Asterisks indicate mean values significantly different from zero (*P < 0.05; **P < 
0.01; ****P < 0.0001) (one sample t test). Data are expressed as means ± SEM of six independent 
experiments, each performed in duplicate.  
 
[35S]GTPS assays. To evaluate the functional activity of C2 on CBRs, [35S]GTPS assays were 
carried out in the presence of [35S]GTPγS (0.1 nM), GDP (30 µM), GTPγS (30 µM), with CHO cell 
membranes (1 mg/ml) overexpressing hCB1Rs or hCB2Rs and in the presence of CP55940, a full 
agonist of both CBRs. The choice of a C2 concentration of 100 nM for these experiments was 
influenced by CB1R and CB2R binding data. The effects of C2 on the modulation of CBR-mediated 
signaling was studied by measuring [35S]GTPγS receptor binding (Figure 5).  
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Figure 5. CB1R [
35S]GTPγS binding assays (left) and CB2R [35S]GTPγS binding assays (right) 
performed with CP55940 and compound C2. . Asterisks indicate mean values significantly different 
from zero (*P < 0.05; **P < 0.01; ***P < 0.001) (Student’s unpaired t test). Data are expressed as 
means ± SEM of six and twelve independent experiments for CB1R and CB2R respectively, each 
performed in duplicate.   
 
The CP55940-induced stimulation of [35S]GTPγS CB1R binding was not significantly altered by 
100 nM C2 (Figure 5). This result suggests that although this concentration of compound C2 
increases the binding of the orthosteric ligand [3H]CP55940 to CB1Rs, this enhancement does not 
significantly affect the ability of CP55940 to activate CB1Rs. However, the current data is not 
sufficient to indicate C2 as SAM for CB1R. 
Conversely C2 appeared to target CB2Rs in a very promising and interesting manner (Figure 5). 
Thus, the ability of CP55940 to stimulate [35S]GTPγS binding to CB2Rs was significantly enhanced 
by 100 nM C2. Furthermore as shown in Figure S4 (Supporting Information), in the absence of the 
orthosteric ligand, compound C2 did not produce any stimulation or inhibition of [35S]GTPγS binding 
to CB2Rs. Collectively, these data suggest that C2 acts as a PAM of CB2Rs. 
Further studies should be carried out with the aim to investigate the allosteric effects of C2 more 
fully (e.g. more concentrations and additional functional in vitro assays) and to highlight different 
behaviors at other CB1R- and CB2R-mediated signaling pathways (e.g. cAMP production, -arrestin, 
ion channels). 
Consequently, the study of this compound was extended by performing [35S]GTPγS receptor 
binding assays using one or the other of the two major endocannaboinoids, anandamide (AEA) and 
2-arachidonoylglycerol (2-AG), as CB2R agonists, rather than CP55940. As shown in Figure 6, 100 
nM of C2 significantly enhanced the stimulation of [35S]GTPγS binding to CB2R induced by 2-AG, 
but not the enhancement induced by AEA. Thus, it is likely that C2 would be able to facilitate the 
activation of CB2Rs by low concentrations of endogenously-released 2-AG, although not by 
endogenously-released AEA. 
 
 
Figure 6. CB2R [
35S]GTPγS binding assays performed in the presence of C2 with 2-
arachidonoylglycerol (2-AG) (left) or anandamide (AEA) (right). Asterisks indicate mean values 
significantly different from zero (*P < 0.05; **P < 0.01) (Student’s unpaired t test). Data are 
expressed as means ± SEM of six independent experiments, each performed in duplicate.  
 
Dissociation Kinetic Assays. In order to better characterize the postulated allosteric action of 
derivative C2, some dissociation kinetic assays in the absence or in the presence of C2 (Figure 7) 
were performed. These assays were carried out with the CB1/CB2R ligand [
3H]CP55940 (1 µM), C2 
(100 nM) and CHO cell membranes (1 mg/ml) overexpressing hCB2Rs. Dissociation was monitored 
from +0.5 to +120 min at 25 °C. As shown in Figure 7, [3H]CP55940 dissociation was completely 
prevented by 100 nM of C2 for at least 2 hours. The absence of [3H]CP55940 dissociation from 
CB2Rs was in line with the increased binding of [
3H]CP55940 induced by C2 in binding experiments. 
These findings support our hypothesis that C2 targets an allosteric binding site of the CB2Rs. Each 
point on the graph represents a mean of 4 replicates.   
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 Figure 7. Dissociation of [3H]CP55940 from CB2Rs in the presence or absence of C2. Data are 
expressed as means ± SEM of four independent experiments, each performed in duplicate.  
 
 
Inhibitory activity on MAGL. Finally, in line with the hypothesis that C2 enhanced 2-AG-
induced stimulation of [35S]GTPγS binding to the CB2Rs by acting as a CB2R PAM, evidence was 
obtained that C2 did not induce this enhancement by inhibiting monoacylglycerol lipase (MAGL), 
the main 2-AG degrading enzyme. This evidence was obtained from experiments in which the 
enzymatic activity of human isoforms of MAGL was measured by using a colorimetric assay that 
exploits 4-nitrophenylacetate (4-NPA) as a non-specific chromogenic substrate for MAGL and by 
measuring the absorbance values at 405 nm due to 4-nitrophenol (PNP) released from 4-NPA, upon 
enzymatic hydrolysis.25 The obtained results showed that C2 produced no significant inhibition of 
MAGL at < 10 µM. 
 
Antinociceptive Effects of C2 in Animal Models of Neuropathic Pain. Neuropathic pain may 
be induced by traumatic injury, metabolic challenges and chemotherapeutic agents. 
Pharmacotherapies used to treat neuropathic pain produce inadequate pain relief and/or unwanted 
side effects. Thus, the identification of novel therapeutic approaches with limited side effect profiles 
remains an urgent medical need. Cannabinoids suppress behavioural responses to noxious stimulation 
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and suppress nociceptive transmission through activation of CB1Rs and CB2Rs. Moreover, the CB2Rs 
are upregulated in the CNS and dorsal root ganglia by pathological pain states and they were 
identified as a therapeutic target for treating pathological pain states.26 These observations prompted 
us to examine the ability of C2 to alleviate signs of neuropathic pain in a mouse model of nociceptive 
behavior caused by the chemotherapeutic agent, oxaliplatin (OXP). 
A daily treatment with the neurotoxic compound oxaliplatin (2.4 mg kg-1 intraperitoneally - i.p.) 
progressively decreased the pain threshold of mice evaluated as hypersensitivity to a cold non-
noxious stimulus (allodynia-like measurements; cold plate test).27 The licking latency decreased to 
9.7 ± 0.9 s in comparison to control mice (18.2 ±0.6 s) treated with vehicle (Figure 8). The effect of 
single oral (p.o.) administration of four different doses of derivative C2 (1, 5, 10, 20 mg kg-1) on 
oxaliplatin-treated mice is shown in Figure 8. C2 significantly increased licking latency in the animals 
starting from 5 mg kg-1. The doses of 5 and 10 mg kg-1 of C2 were equally effective between 30 and 
60 min after administration (Figure 8). The effect of the higher 20 mg kg-1 dose was detectable within 
15 min and lasted 60 min, reducing animal pain threshold back to the value of controls between +30 
and +45 min. 
 
 
Figure 8. Neuropathic pain modulation by C2. Hypersensitivity was induced by repeated 
treatment with oxaliplatin, the response to a thermal stimulus was evaluated by the cold plate test 
measuring the latency (s) to pain-related behaviors (lifting or licking of the paw). Tests were 
performed on day 15. C2 or vehicle were administered p.o., measurements were performed 15, 30, 
45, 60 and 75 min. after treatment. Each point on the graph represents a mean of 16 individual values 
obtained from 16 mice analyzed in 2 different experimental sets. ^^P < 0.01 vs vehicle + vehicle 
treated mice. *P < 0.05 and **P < 0.01 vs oxaliplatin + vehicle treated mice. ANOVA followed by 
Bonferroni test was performed. 
 
Additional experiments were performed to establish if an increase in endocannabinoid levels induced 
by a monoacylglycerol lipase (MAGL) inhibitor would potentiate the effect of C2. The used MAGL 
inhibitor F (compound 4a in the reference28) was previously reported in literature and it showed to be 
efficacious in the same model of neuropathic pain.28 It was administered p.o. at a minimum active 
dose of 1 mg kg-1 15 min before compound C2 (used at the completely inactive dose 1 mg kg-1, and 
the partially effective dose 10 mg kg-1). The effect observed after the co-administration of C2 with 
the MAGL inhibitor, was significantly increased in comparison to that produced by each compound 
administered alone (Figure 9). The lowest dose of C2 (1 mg kg-1) became able to fully revert 
oxaliplatin-induced hypersensitivity when administered after the MAGL inhibitor F (1 mg kg-1). The 
analysis of synergism performed by the Chou-Talalay method29 revealed a combination index (CI; 
CompuSyn software) 0.20123 considered as “synergism”. MAGL inhibitor, administered alone at 
dose 1 mg kg-1 had a partial pain relieving efficacy (Figure 9). 
 
 Figure 9. Neuropathic pain. Effect of C2 administered 15 min after the MAGL inhibitor F. 
Measurements were performed 15, 30, 45, 60 and 75 min after the administration (cold plate test). 
Control mice were treated with vehicle. Each point on the graph represents a mean of 16 individual 
values obtained from 16 mice analyzed in 2 different experimental sets. ^^P < 0.01 vs vehicle + 
vehicle treated mice. *P < 0.05 and **P < 0.01 vs oxaliplatin + vehicle treated mice. °°P < 0.01 vs 
oxaliplatin + C2 treated mice. ANOVA followed by Bonferroni test was performed. 
 
Finally, the possible predominance of a CBR subtype in the anti-neuropathic effect of C2 was 
studied. Selective CB1R (SR141716A) and CB2R (SR144528) antagonists were administered i.p. 15 
min before C2 (20 mg kg-1 p.o.; Figure 10). The efficacy of C2 was strongly decreased by pre-treating 
with SR144528 (10 mg kg-1 i.p.), whereas SR141716A only reduced the duration of C2 effect without 
affecting its anti-hyperalgesic efficacy. A main involvement of CB2Rs is indicated as 
pharmacodynamic mechanism of C2 efficacy against chemotherapy-induced neuropathic pain. 
 
 Figure 10. Neuropathic pain. Effects of CB1R and CB2R antagonism on C2 pain relieving 
efficacy. Measurements were performed 15, 30, 45, 60 and 75 min after the administration of C2. 
Control mice were treated with vehicle. Each point on the graph represents a mean of 16 individual 
values obtained from 16 mice analyzed in 2 different experimental sets. ^^P < 0.01 vs vehicle + 
vehicle treated mice. *P < 0.05 and **P < 0.01 vs oxaliplatin + vehicle treated mice. ANOVA 
followed by Bonferroni test was performed. 
 
Conclusion 
In conclusion, we have presented evidence that compound C2 is the first ever synthesized CB2R 
PAM. This compound was obtained from the CBR orthosteric ligands, 2-oxopyridine-3-carboxamide, 
simply by changing its amide side chain into a retro-amide side chain. 
Derivative C2 behaved as a potent CB2R PAM as indicated by its ability, at 1 nM to 1 µM, to 
produce marked increases in the binding of [3H]CP55940 to CB2Rs. At 100 nM, C2 also significantly 
enhanced the ability of CP55940 and 2-AG, but not of AEA, to stimulate [35S]GTPγS binding to 
CB2Rs. As expected for an allosteric modulator, C2 did not affect signs of CB2R receptor signalling 
in the [35S]GTPγS assay, in the absence of a CB2R agonist. Interestingly, C2 significantly improved 
the ability of 2-AG, but not of AEA, to stimulate [35S]GTPγS binding to CB2Rs. Thus, derivative C2 
would be able to activate CB2Rs by low concentrations of endogenously-released 2-AG and also it 
could potentiate the pharmacological activity of MAGL inhibitors. 
Although we studied only a small compound library, the obtained results suggest that the C and D 
series of compounds display interesting SARs. Undoubtedly, it was the introduction of a retro-amide 
sidechain into compounds A and B that converted them into CB2R allosteric modulators (C and D). 
Also the bromo substituent in position 5 seems to be important, because its replacement with an H or 
with other groups abolished all signs of allosteric activity. Furthermore, the substitution of the methyl 
group in position 4 with an OH group (compound E1) reduced signs of allosteric activity. The display 
of such activity also seems to require the presence of a substituent at position 1 of the pyridine ring, 
as suggested by the finding that compound 3 lacks any detectable allosteric activity.  
The new CB2R PAM, C2, was tested in cold allodynia assays to investigate its effect on 
neuropathic pain. Results showed that derivative C2, after oral administration, dose-dependently 
reversed the lowering of the threshold to cold stimuli (cold plate test) induced by oxaliplatin. As 
demonstrated by pharmacological antagonism, this effect is predominantly mediated by the CB2Rs. 
Finally, C2 potentiated the anti-allodynic effect of the MAGL inhibitor F, which previously 
showed to be efficacious in the same model of neuropathic pain.28  
Our findings support our hypothesis that compound C2 acts as a CB2R PAM both in vitro and in 
vivo. Moreover, C2 could beneficially influence the CNS damages induced by neuropathies. Several 
cell types (including microglia, astrocytes and oligodendrocytes) are involved in the maladaptive 
plasticity of the nervous tissue that is thought to be the basis of chronic pain states.30 The widespread 
expression (for anatomic areas and cell types)31 of the CB2Rs makes its regulation a powerful 
therapeutic approach. The antinociceptive effects of C2 need to be further explored as this compound 
might be a good candidate for clinical development. Recently, based on a homology model, an 
allosteric binding pocket was postulated to exist adjacent to the CB2R orthosteric binding site.
8,14 The 
CB2R PAM C2 could be useful for the characterization of such putative binding site(s), a crucial step 
for the future development of CB2R allosteric modulators. In addition, a better understanding of the 
physiological consequences of CB2R allosteric modulation might lead to novel pharmacotherapies 
that rely on this pharmacological action. 
 
EXPERIMENTAL SECTION 
Chemistry. Commercially available reagents were purchased from Sigma Aldrich or Alfa Aesar 
and used without purification. 1H NMR and 13C NMR spectra were recorded on a Bruker AVANCE 
III™ 400 spectrometer (operating at 400 MHz). Chemical shift (δ) are reported in parts per million 
related to the residual solvent signal, while coupling constants (J) are expressed in Hertz (Hz) 
Catalitic hydrogenation was performed with CLAIND H2 generator, type HG2200 (flow meter: 200 
ml/min; outlet pressure: 1-6 bar; operating temperature: 5-40°C). A Bechman HPLC instrument 
equipped with a System Gold Solvent Delivery module (Pumps) 125, System Gold UV/VIS Detector 
166, Detector set to 280 nm was employed. Analyses were performed on a reverse phase C18 column 
(Phenomenex 250 x 4.6 mm, 5 mm particle size, Gemini). The mobile phase was constituted by a 
H2O/AcOH (0.1% v/v) (eluent A) and ACN (eluent B). A linear gradient starting from 50% of B, 
changing to 100% of B over 20 min., and returning to the initial conditions over 10 min., was used 
for all the compounds. For the HPLC analysis, all target compounds (i.e., assessed in biological 
assays) were ≥95% pure. Evaporation was carried out in vacuo using a rotating evaporator. Silica gel 
flash chromatography was performed using silica gel 60 Å (0.040-0.063 mm; MERK). Reactions was 
monitored by TLC on Merck aluminum silica gel (60 F254) plates that were visualized under a UV 
lamp ( = 254 nm). Melting points were determined on a Kofler hot-stage apparatus and are 
uncorrected. 
3-Amino-2-hydroxy-4-methylpyridine (1). Pd/C (100.0 mg) was added to a solution of the 
commercially available 2-hydroxy-4-methyl-3-nitropyridine (1.00 g, 6.49 mmol) in methanol. The 
reaction mixture was stirred under hydrogen at room temperature for 12 h and then was filtered under 
vacuum using celite. The filtrate was evaporated under reduced pressure to afford the desired 
compound 1 as solid (0.80 g, 99%). 1H-NMR (CDCl3 δ): 12.36 (bs,1H), 6.57 (d, 1H, J=7.2 Hz), 5.88 
(d, 1H, J=7.2 Hz), 3.97 (bs, 2H), 2.25 (s, 3H). 
N-(1,2-dihydro-4-methyl-2-oxopyridin-3-yl)cycloheptanecarboxamide (2). 
Cycloheptanecarboxylic acid (0.700 ml, 4.99 mmol) was dissolved in SOCl2 (2.60 ml, 36.5 mmol) in 
a vial under nitrogen flux. The solution was stirred at 76 °C for 3 hours and then the excess of SOCl2 
was removed by evaporation under nitrogen flux. The obtained acyl chloride was added dropwise to 
a solution of the amino derivative 1 (310 mg, 2.50 mmol) and triethylamine (0.700 ml, 4.99 mmol) 
in anhydrous toluene (46.5 ml) and anhydrous DMF (6.20 ml) in a round bottom flask at 0 °C. The 
reaction mixture was stirred at room temperature for 48 hours. Then the solvent was removed under 
reduced pressure to give a residue which was dissolved in CHCl3 and washed three times with water. 
Subsequently, the organic phase was dried over Na2SO4, filtered and evaporated under reduced 
pressure. The brown solid obtained was purified by flash chromatography on silica gel (ethyl acetate, 
2% acetic acid) to give a solid which was triturated in hexane to afford 2 as white solid (372 mg, 
60%). Mp: dec. >150 °C (crystallized from hexane). 1H-NMR (CDCl3 δ): 7.62 (bs, 1H), 7.10 (d, 1H, 
J=6.4 Hz), 6.26 (d, 1H, J=6.8 Hz), 2.53-2.48 (m, 1H), 2.16 (s, 3H), 2.02-1.98 (m, 2H), 1.81-1.71 (m, 
4H), 1.59-1.53 (m, 6H). 
N-(5-bromo-1,2-dihydro-4-methyl-2-oxo-pyridin-3-yl)cycloheptanecarboxamide (3). A 
solution of Br2 (0.11 ml, 2.08 mmol) in CHCl3 (2.1 ml) was added dropwise to a solution of the 
compound 2 (518 mg, 2.08 mmol) in CHCl3 (3.5 ml) at room temperature. Reaction mixture was 
stirred at room temperature overnight and then was washed four times with a saturated aqueous 
solution of Na2S2O3. The organic phase was dried over Na2SO4, filtered and evaporated under reduced 
pressure. The solid residue was crystallized from hexane to give 3 as a white solid (578 mg, 85%). 
Mp: 217-219 °C. 1H-NMR (CDCl3 δ): 7.40 (bs, 1H), 7.39 (s, 1H), 2.56-2.49 (m, 1H), 2.21 (s, 3H), 
2.06-2.00 (m, 2H), 1.85-1.73 (m, 4H), 1.61-1.55 (m, 6H). 13C-NMR (CDCl3 δ): 176.32, 158.04, 
134.75, 128.17, 127.41, 100.81, 48.21, 31.57, 28.40, 26.47, 19.68. HPLC analysis: retention time = 
5.1 min; peak area, 95.5% (280 nm). 
N-(5-chloro-1,2-dihydro-4-methyl-2-oxo-pyridin-3-yl)cycloheptanecarboxamide (4). A 
solution of N-chlorosuccinimide (270 mg, 2.02 mmol) in acetonitrile (2.0 mL) was added to a 
suspension of the derivative 2 (500 mg, 2.02 mmol) in acetonitrile (3.0 mL). The reaction mixture 
was refluxed overnight. Then, the solvent was removed under reduced pressure and the residue was 
treated with water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered 
and concentrated under reduced pressure to give a yellow solid purified by flash chromatography on 
silica gel using ethyl acetate/petroleum ether 7:3 and 1% acetic acid as eluent, to give a yellow solid 
which was triturated in hexane to afford compound 4 as white solid (274 mg, 48%). Mp: 200 °C 
(dec), (crystallized from hexane). 1H-NMR (CDCl3 δ): 8.73 (bs, 1H), 7.52 (s, 1H), 7.29 (bs, 1H), 2.54 
(m, 1H), 2.18 (s, 3H), 2.04-2.01 (m, 2H), 1.83-1.73 (m, 4H), 1.66-1.49 (m, 6H). 
3-amino-2-hydroxy-6-methylpyridine (5). Compound 5 was prepared as described for 
compound 1, starting from 2-hydroxy-6-methyl-3-nitropyridine. Yield: 99%. 1H-NMR (CDCl3 δ): 
12.20 (bs, 1H), 6.78 (d, 1H, J=6.8 Hz), 6.09 (d, 1H, J=6.8 Hz), 4.03 (bs, 2H), 2.10 (s, 3H). 
N-(1,2-dihydro-6-methyl-2-oxopyridin-3-yl)cycloheptanecarboxamide (6). A solution of 
cycloheptanecarboxylic acid (0.870 ml, 6.32 mmol) in anhydrous DMF (15.70 ml) was stirred in an 
ice-bath. TBTU (2440 mg, 7.59 mmol) and triethylamine (2.40 ml, 17.70 mmol) were added at 0 °C. 
After 30 minutes, compound 5 (785 mg, 6.32 mmol) was added and the reaction mixture was stirred 
at 0 °C for 30 minutes and then at room temperature overnight. The solvent was removed under 
reduced pressure. The solid residue was dissolved in CHCl3 and washed with water. The organic 
phase was dried over Na2SO4, filtered and evaporated under reduced pressure. The brown solid thus 
obtained was purified by flash chromatography on silica gel using ethyl acetate/petroleum ether 8:2 
as eluent to give a yellow solid which was crystallized from hexane to afford compound 6 as white 
solid (1.290 g). Yield: 82 %. Mp: 182-185 °C. 1H-NMR (CDCl3 δ): 11.77 (bs, 1H), 8.39 (d, 1H, J=7.6 
Hz), 8.16 (bs, 1H), 6.09 (d, 1H, J=7.6 Hz), 2.47-2.44 (m, 1H), 2.32 (s, 3H), 2.01-1.95 (m, 2H), 1.83-
1.71 (m, 4H), 1.62-1.49 (m, 6H). 
N-(5-bromo-1,2-dihydro-6-methyl-2-oxo-pyridin-3-yl)cycloheptanecarboxamide (7). 
Compound 7 was prepared starting from derivative 6, as described for compound 3 and it was purified 
by flash chromatography on silica gel using ethyl acetate/petroleum ether 7:3. Yield: 89%. 1H-NMR 
(CDCl3 δ): 12.25 (bs, 1H), 8.64 (s, 1H), 8.10 (s, 1H), 2.50-2.41 (m, 1H), 2.01 (s, 3H), 1.75-1.61 (m, 
6H), 1.84-1.76 (m, 4H), 1.99-1.94 (m, 2H). 
N-(5-chloro-1,2-dihydro-6-methyl-2-oxo-pyridin-3-yl)cycloheptanecarboxamide (8). 
Compound 8 was prepared starting from derivative 6, as described for compound 4 and it was purified 
by flash chromatography on silica gel using ethyl acetate/petroleum ether 1:1, Yield: 19%. Mp: 240-
246 °C (crystallized from hexane). 1H-NMR (CDCl3 δ): 11.99 (bs, 1H), 8.55 (s, 1H), 8.11 (bs, 1H), 
2.50-2.48 (m, 1H), 2.39 (s, 3H), 2.01-1.96 (m, 2H), 1.85-1.81 (m, 4H), 1.79-1.54 (m, 6H). 
N-(1,2-dihydro-5-fluoro-6-methyl-2-oxo-pyridin-3-yl)cycloheptanecarboxamide (9). 1-
chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2] octanebis(tetrafluoroborate) (Selectfluor®)(1.200 
g, 3.39 mmol) was added at room temperature to a suspension of compound 6 (700 mg, 2.82 mmol) 
in acetonitrile. Reaction mixture was refluxed for 12 hours. Then, the solvent was removed under 
reduced pressure and the residue was treated with ethyl acetate and washed three times with water. 
The organic phase was dried over Na2SO4, filtered and evaporated under reduced pressure. The black 
solid thus obtained was purified by flash chromatography on silica gel using petroleum ether/ethyl 
acetate 1:1 as eluent, to give compound 9 (52.0 mg, 0.196 mmol) as a black solid. Yield: 7% Mp: 95-
98 °C (crystallized from hexane). 1H-NMR (CDCl3 δ): 8.48 (d, 1H, J=10.4 Hz), 8.16 (bs, 1H), 2.51-
2.46 (m, 1H), 2.30 (d, 3H, J=2.8 Hz), 2.01-1.95 (m, 2H), 1.81-1.75 (m, 4H), 1.62-1.53 (m, 6H). 
3-amino-2,4-dihydroxypyridine (10). Compound 10 was prepared starting from 2,4-dihydroxy-
3-nitropyridine, as described for compound 1. Yield: 33%. 1H-NMR (MeOD δ): 12.26 (bs,1H), 6.84 
(d, 1H, J= 7.2 Hz); 6.13 (d, 1H, J= 7.2 Hz), 4.03 (bs, 2H). 
N-(1,2-dihydro-4-hydroxy-2-oxopyridin-3-yl)cycloheptanecarboxamide (11). Compound 11 
was prepared starting from derivative 10, as described for compound 2 and it was purified by 
trituration with MeOH and then with Et2O. Yield: 25%. Mp: dec. >130 °C (crystallized from hexane). 
1H-NMR (CDCl3 δ): 12.71 (bs, 1H); 11.28 (bs, 1H); 8.39 (s, 1H), 7.03 (d, 1H, J= 7.2 Hz), 6.08 (d, 
1H, J= 7.2 Hz) 2.58-2.57 (m, 1H), 2.02-1.98 (m, 2H), 1.83-1.72 (m, 4H), 1.65-1.50 (m, 6H). 
N-(5-bromo-1,2-dihydro-4-hydroxy-2-oxo-pyridin-3-yl)cycloheptanecarboxamide (12). 
Compound 12 was prepared starting from derivative 11, as described for compound 3 and it was 
purified by flash chromatography on silica gel using ethyl acetate/petroleum ether 7:3. Yield: 68 %. 
1H-NMR (CDCl3 δ): 8.34 (bs, 1H), 7.35 (s, 1H), 2.60-2.55 (m, 1H), 2.02-1.98 (m, 2H), 1.83-1,71 (m, 
4H), 1.61-1.51 (m, 6H). 
N-[1,2-dihydro-1-(4’-fluorobenzyl)-4-methyl-2-oxo-pyridin-3yl]cycloheptanecarboxamide 
(C1). An amount of 214.0 mg of CsF (1.41 mmol) was added to a solution of of 1,2-dihydro-pyridin-
3-cycloheptanecarboxamide 2 (117.0 mg, 0.470 mmol) in anhydrous DMF (1.40 ml). After 1 hour at 
room temperature, 4-fluorobenzyl chloride (0.17 ml, 1.41 mmol) was added dropwise and the mixture 
was stirred at 50 °C overnight. After cooling, the reaction mixture was concentrated under reduced 
pressure, treated with ice-water and then extracted with CH2Cl2. The organic phase was dried over 
Na2SO4, filtered and evaporated under reduced pressure. The yellow oil obtained was purified by 
flash chromatography on silica gel using petroleum ether/ethyl acetate 1:1), to give C1 as white solid 
(67.0 mg, 40%). Mp: 160-165 °C (crystallized from hexane). 1H-NMR: (CDCl3 δ): 7.43 (bs, 1H), 
7.28-7.25 (m, 2H), 7.04-7.00 (m, 3H), 6.10 (d, 1H, J=7.2 Hz), 5.07 (s, 2H), 2.53-2.46 (m, 1H), 2.12 
(s, 3H), 2.07-2.00 (m, 2H), 1.83-1.72 (m, 4H), 1.59-1.52 (m, 6H). 13C-NMR: (CDCl3 δ): 176.06, 
162.65 (d, J=246.0 Hz), 159.56, 142.40, 132.04 (d, J=3.2 Hz), 131.67, 130.02 (d, J=9.1 Hz), 125.85, 
115.95 (d, J=22.0 Hz), 110.21, 51.99, 48.04, 31.92, 28.27, 26.77, 19.83. HPLC analysis: retention 
time = 8.6 min; peak area 99.7% (280 nm). 
N-[5-bromo-1,2-dihydro-1-(4’-fluorobenzyl)-4-methyl-2-oxo-pyridin-
3yl]cycloheptanecarboxamide (C2). Compound C2 was prepared starting from derivative 3, as 
described for compound C1 and it was purified by flash chromatography on silica gel using petroleum 
ether/ethyl acetate 7:3 as eluent. Yield: 58% Mp: 167-170 °C (crystallized from hexane). 1H-NMR 
(CDCl3 δ): 7.48 (bs, 1H), 7.33 (s, 1H), 7.30-7.28 (m, 2H), 7.06-7.02 (m, 2H), 5.05 (s, 2H), 2.53-2.47 
(m, 1H), 2.15 (s, 3H), 2.06-1.99 (m, 2H), 1.81-1.71 (m, 4H), 1.59-1.52 (m, 6H). 13C-NMR (CDCl3 
δ): 176.08, 162.77 (d, J=246.0 Hz), 158.42, 142.07, 132.10, 131.34 (d, J=4.1 Hz), 130.21 (d, J=9.1 
Hz), 126.60, 116.12 (d, J=22.0 Hz), 104.08, 52.06, 47.94, 31.81, 28.22, 26.70, 20.67. HPLC analysis: 
retention time = 9.5 min; peak area 95.5 % (280 nm). 
N-[1,2-dihydro-1-(4’-fluorobenzyl)-5-(4’-methoxyphenyl)-4-methyl-2-oxo-pyridin-3-
yl]cycloheptanecarboxamide (C3). A mixture of Pd(OAc)2 (2.20 mg, 0.009 mmol) and PPh3 (11.80 
mg, 0.045 mmol) in 2.50 mL of toluene was stirred under nitrogen at room temperature. After 15 
minutes, the suitable boronic acid (37.9 mg, 0.600 mmol), K2CO3 (62,2 mg, 0.450 mmol) and 
compound C2 (130.6 mg, 0.300 mmol) were added. Reaction mixture was stirred at 110 °C overnight. 
After cooling, the reaction was filtered under vacuum using celite, and the filtrate was evaporated 
under reduced pressure. The residue was treated with water and extracted with CHCl3. The combined 
organic layers were washed with brine, dried over anhydrous sodium sulfate, and evaporated to give 
a residue which was purified by flash chromatography on silica gel using petroleum ether/ethyl 
acetate 8:2 as eluent affording C3 as oil (100 mg, 0.216 mmol). Yield: 72%. 1H-NMR (CDCl3 δ): 
7.57 (bs, 1H), 7.32-7.29 (m, 2H), 7.17-7.15 (m, 2H), 7.05-7.00 (m, 3H), 6.92-6.90 (m, 2H), 5.12 (s, 
2H), 3.83 (s, 3H), 2.56-2.51 (m, 1H), 2.07-2.02 (m, 2H), 1.98 (s, 3H), 1.81-1.76 (m, 4H), 1.60-1.58 
(m, 6H). 13C-NMR (CDCl3 δ): 176.15, 162.18 (d, J=245.0 Hz), 159.26, 158.70, 142.25, 135.89, 
131.97 (d, J=32 Hz), 130.92, 130.82, 130.07 (d, J=8.6 Hz), 129.05, 125.85, 123.46, 115.92 (d, J=22.0 
Hz), 113.95, 55.42, 52.00, 47.89, 31.88, 28.26, 26.70, 18.50. HPLC analysis: retention time = 13.2 
min; peak area 98.2 % (280 nm). 
N-[1,2-dihydro-1-(4’-fluorobenzyl)-4-methyl-2-oxo-5-phenyl-pyridin-3-
yl]cycloheptanecarboxamide (C4). Compound C4 was prepared from compound C2, as described 
for compound C3 and it was purified by crystallization from hexane. Yield: 45%. Mp: 143-146 °C 
(crystallized from hexane). 1H-NMR: (CDCl3 δ): 7.54 (bs, 1H), 7.41-7.29 (m, 5H), 7.25-7.24 (m, 2H), 
7.05-7.01 (m, 3H), 5.12 (s, 2H), 2.56-2.51 (m, 1H), 2.07-2.02 (m, 2H), 1.99 (s, 3H), 1.83-1.77 (m, 
4H), 1.60-1.53 (m, 6H). 13C-NMR (CDCl3 δ): 176.05, 162.58 (d, J=243.8 Hz), 158.72, 141.85, 
136.78, 131.93 (d, J=3.2 Hz), 131.00, 130.04 (d, J=8.6 Hz), 129.67, 128.52, 127.72, 126.02, 123.77, 
115.89 (d, J=21.8 Hz), 51.98, 47.81, 31.85, 28.25, 26.67, 18.41. HPLC analysis: retention time = 13.5 
min; peak area 99.6 % (280 nm). 
N-[5-chloro-1,2-dihydro-1-(4’-fluorobenzyl)-4-methyl-2-oxo-pyridin-3-
yl]cycloheptanecarboxamide (C5). Compound C5 was prepared from compound 4, as described for 
compound C1 and it was purified by flash chromatography on silica gel using petroleum ether/ethyl 
acetate 7:3 as eluent to give a light yellow solid which was triturated in hexane to afford C5 as white 
solid. Yield: 39%. Mp: 197-199 °C (crystallized from hexane). 1H-NMR (CDCl3 δ): 7.49 (bs, 1H), 
7.30-7.27 (m, 2H), 7.21 (s, 1H), 7.06-7.02 (m, 2H), 5.06 (s, 2H), 2.53-2.48 (m, 1H), 2.14 (s, 3H), 
2.06-2.00 (m, 2H), 1.81-1.74 (m, 4H), 1.58-1.51 (m, 6H). 13C-NMR (CDCl3 δ): 176.06, 162.72 (d, 
J=246.0 Hz), 158.24, 141.17, 131.33 (d, J=3.2 Hz), 130.17 (d, J=8.6 Hz), 129.62, 126.64, 116.05 (d, 
J=22.0 Hz), 115.75, 52.01, 47.83, 31.77, 28.19, 26.66, 17.86. HPLC analysis: retention time = 11.6 
min; peak area 96.8 % (280 nM).  
N-[1,2-dihydro-1-(4’-fluorobenzyl)-6-methyl-2-oxo-pyridin-3yl]cycloheptanecarboxamide 
(D1). An amount of 35.2 mg (0.879 mmol) of NaH (60% mineral oil dispersion) was added 
portionwise to a solution of 1,2-dihydropyridin-3-cycloheptanecarboxamide 6 (212 mg, 0.854 mmol) 
in DME (1.700 ml) and anhydrous DMF (0.400 ml). After 10 minutes at 0 °C, LiBr (147.6 mg, 1.700 
mmol) was added and the reaction mixture was stirred at room temperature for 15 minutes. After that, 
4-fluorobenzylchloride (0.200 ml, 1.650 mmol) was added dropwise and the mixture was stirred at 
65 °C overnight. After cooling, the solvent was removed under reduced pressure and the obtained 
residue was dissolved in CHCl3 and washed with brine. The organic phase was dried over Na2SO4, 
filtered and evaporated under reduced pressure to obtain a residue which was purified by flash 
chromatography on silica gel using petroleum ether/ethyl acetate 8:2 as eluent giving D1 as oil (79.1 
mg, 0.220 mmol). Yield: 26% 1H-NMR (CDCl3 δ): 8.31 (bs, 1H), 8.30 (d, 1H, J=7.6 Hz), 7.11-7.08 
(m, 2H), 6.99-6.96 (m, 2H), 6.09 (d, 1H, J=7.6 Hz), 5.31 (s, 2H), 2.44-2.43 (m, 1H), 2.26 (s, 3H), 
1.99-1.95 (m, 2H), 1.79-1.70 (m, 4H), 1.58-1.48 (m, 6H). 13C-NMR (CDCl3 δ): 176.44, 162.27 (d, 
J=245.0 Hz), 158.75, 137.97, 131.86, 128.25 (d, J=8.6 Hz), 127.36, 122.34, 115.93 (d, J=22.1 Hz), 
107.32, 48.58, 47.62, 31.69, 28.31, 26.64, 20.14. HPLC analysis: retention time = 13.2 min; peak 
area 97.1 % (280 nm). 
N-[5-bromo-1,2-dihydro-1-(4’-fluorobenzyl)-6-methyl-2-oxo-pyridin-3-
y]cycloheptanecarboxamide (D2). Compound D2 was prepared from derivative 7, as described for 
compound D1 and it was purified by flash column chromatography on silica gel using petroleum 
ether/ethyl acetate 8:2 as eluent. Yield: 40%. Mp: 124-127 °C (crystallized from hexane). 1H-NMR 
(CDCl3 δ): 8.61 (s, 1H), 8.31 (bs, 1H), 7.12-7.09 (m, 2H), 7.04-7.00 (m, 2H), 5.39 (s, 2H), 2.48-2.43 
(m, 1H), 2.42 (s, 3H), 2.02-1.94 (m, 2H), 1.82-1.71 (m, 4H), 1.63-1.54 (m, 6H). 13C-NMR (CDCl3 
δ): 176.33, 162.19 (d, J=246.0 Hz), 157.76, 135.64, 131.20 (d, J=3.2 Hz), 128.05 (d, J=8.1 Hz), 
127.46, 125.78, 115.91 (d, J=22.0 Hz), 101.53, 48.77, 48.23, 31.42, 28.18, 26.39, 19.49. HPLC 
analysis: retention time = 17.6 min; peak area 98.1 % (280 nM). 
N-[1,2-dihydro-1-(4’-fluorobenzyl)-5-phenyl-6-methyl-2-oxo-pyridin-3-yl]cycloheptane 
carboxamide (D3). Compound D3 was prepared starting from derivative D2, as described for 
compound C3 and it was purified by flash column chromatography on silica gel using petroleum 
ether/ethyl acetate 8:2 as eluent. Yield: 13%. 1H-NMR (CDCl3 δ): 8.45 (s, 1H), 8.38 (bs, 1H), 
7.38−7.28 (m, 4H), 7.25-7.23 (m, 3H), 7.17-7.01 (m, 2H), 5.44 (s, 2H), 2.46−2.43 (m, 1H), 2.24 (s, 
3H), 2.01−1.95 (m, 2H), 1.79−1.71 (m, 4H), 1.59−1.49 (m, 6H). 13C-NMR (CDCl3 δ): 176.47, 162.29 
(d, J=244.0 Hz), 158.22, 139.27, 135.05, 132.00, 129.84, 128.53, 128.25 (d, J=8.6 Hz), 127.43, 
126.75, 125.23, 121.35, 115.99 (d, J=22.0 Hz), 48.46, 48.16, 31.68, 28.42, 26.60, 17.56. HPLC 
analysis: retention time = 18.0 min; peak area 95.8 % (280 nm). 
N-[1,2-dihydro-1-(4’-fluorobenzyl)-5-(4’-methoxyphenyl)-6-methyl-2-oxo-pyridin-3-
yl]cycloheptanecarboxamide (D4). Compound D4 was prepared starting from compound D2, as 
described for compound C3 and it was purified by flash column chromatography on silica gel using 
petroleum ether/ethyl acetate 8:2 as eluent. Yield: 19%. 1H-NMR (CDCl3 δ): 8.43 (s, 1H), 8.38 (bs, 
1H), 7.17-7.13 (m, 4H), 7.05-7.01 (m, 2H), 6.90-6.88 (m, 2H), 5.43 (s, 2H), 3.83 (s, 3H), 2.48-2.43 
(m, 1H), 2.23 (s, 3H), 2.00-1.97 (m, 2H), 1.80-1.74 (m, 4H), 1.52-1.50 (m, 6H). 13C-NMR (CDCl3 
δ): 176.43, 162.24 (d, J=244.0 Hz), 158.93, 158.14, 135.03, 131.99 (d, J=3.2 Hz), 130.89, 128.22 (d, 
J=8.6 Hz), 126.61, 125.47, 120.95, 115.94 (d, J=21.8 Hz), 113.90, 55.42, 48.44, 48.16, 31.65, 28.38, 
26.58, 17.53. HPLC analysis: retention time = 17.3 min; peak area, 99.0 % (280 nm). 
N-[5-chloro-1,2-dihydro-1-(4’-fluorobenzyl)-6-methyl-2-oxo-pyridin-3-
yl]cycloheptanecarboxamide (D5). Compound D5 was prepared starting from compound 8, as 
described for compound D1 and it was purified by crystallization from hexane. Yield: 36%. Mp: 116-
119 °C (crystallized from hexane). 1H-NMR (CDCl3 δ): 8.49 (s, 1H), 8.33 (bs, 1H), 7.12-7.09 (m, 
2H), 7.04-7.00 (m, 2H), 5.37 (s, 2H), 2.46-2.43 (m, 1H), 2.38 (s, 3H), 2.04-1.94 (m, 2H), 1.81-1.71 
(m, 4H), 1.61-1.48 (m, 6H). 13C-NMR (CDCl3 δ): 176.39, 162.24 (d, J=245.0 Hz), 157.56, 134.35, 
131.26 (d, J=3.2 Hz), 128.11 (d, J=8.1 Hz), 127.37, 123.48, 115.95 (d, J=22.0 Hz), 113.35, 48.50, 
48.30, 31.47, 28.21, 26.44, 16.68.  HPLC analysis: retention time = 16.9 min; peak area 98.2 % (280 
nm). 
N-[1,2-dihydro-5-fluoro-1-(4’-fluorobenzyl)-6-methyl-2-oxo-pyridin-3-
yl]cycloheptanecarboxamide (D6). Compound D6 was prepared starting from compound 9, as 
described for compound D1, and it was purified by flash column chromatography on silica gel using 
petroleum ether/ethyl acetate 8:2. Yield: 24%. 1H-NMR (CDCl3 δ): 8.43 (d, 1H, J=10.4 Hz), 8.40 
(bs, 1H), 7.14-7.11 (m, 2H), 7.04-7.00 (m, 2H), 5.32 (s, 2H), 2.48-2.43 (m, 1H), 2.25 (d, 3H, J=3.2 
Hz), 2.05-1.95 (m, 2H), 1.80-1.74 (m, 4H), 1.55-1.52 (m, 6H). 13C-NMR (CDCl3 δ): 176.54, 162.33 
(d, J=245.0 Hz), 156.74, 145.52 (d, J=224.2 Hz), 131.48 (d, J=3.2 Hz), 128.30 (d, J=8.6 Hz), 127.23 
(d, J=13.0 Hz), 123.12 (d, J=29.1 Hz), 116.02 (d, J=21.0 Hz), 114.34 (d, J=32.4 Hz), 48.45, 47.78, 
31.56, 28.28, 26.56, 11.78. HPLC analysis: retention time = 15.1 min; peak area 96.3 % (280 nm). 
N-(5-bromo-1,2-dihydro-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-pyridin-3-
yl)cycloheptanecarboxamide (E1). Compound E1 was prepared from compound 12, as described 
for compound C1 and it was purified by flash column chromatography on silica gel using petroleum 
ether/ethyl acetate 8:2 as eluent. Yield: 8%. Mp: 73-76 °C (crystallized from hexane).  1H-NMR 
(CDCl3 δ): 13.46 (bs, 1H), 8.51 (bs, 1H), 7.30 (s, 1H), 7.28-7.24 (m, 2H), 7.08-7.03 (m, 2H), 5.06 (s, 
2H), 2.61-2.52 (m, 1H), 2.05-1.97 (m, 2H), 1.85-1.68 (m, 4H), 1.62-1.44 (m, 6H). 13C-NMR (CDCl3 
δ): 178.70, 161.56, 132.50, 131.40, 129.94 (d, J=8.6 Hz), 116.19 (d, J=21.8 Hz), 112.40, 97.30, 51.88, 
47.72, 31.85, 28.09, 26.50. HPLC analysis: retention time = 15.6 min; peak area 95.8% (280 nM). 
 
Biological Evaluations 
CHO cells. CHO cells stably transfected with cDNA encoding human cannabinoid CB1Rs or 
CB2Rs were maintained at 37°C and 5% CO2 in Gibco
™ Ham’s F-12 Nutrient Mix supplied by Fisher 
Scientific UK Ltd that was supplemented both with 2 mM L-glutamine, 10% FBS and 0.6% 
penicillin-streptomycin, all also supplied by Fisher Scientific UK Ltd, and with the disulphate salt of 
G418 [(2R,3S,4R,5R,6S)-5-amino-6-{[(1R,2S,3S,4R,6S)-4,6-diamino-3-{[(2R,3R,4R,5R)-3,5-
dihydroxy- 5-methyl-4-(methylamino)oxan-2-yl]oxy}-2-hydroxy cyclohexyl]oxy}-2-[(1R)-1-
hydroxyethyl]oxane-3,4-diol; 600 mg·mL-1] supplied by Sigma-Aldrich UK. All cells were exposed 
to 5% CO2 in their respective media, and were passaged twice a week using non-enzymatic cell 
dissociation solution. For membrane preparation, cells were removed from flasks by scraping, 
centrifuged, and then frozen as a pellet at -20 °C until required. Before use in a radioligand binding 
assay, cells were defrosted, diluted in Tris buffer (50 mM Tris–HCl and 50 mM Tris–base).  
Radioligand displacement assay. The assays were carried out with [3H]CP55940 and Tris 
binding buffer (50 mM Tris–HCl, 50 mM Tris–base, 0.1% BSA, pH 7.4), total assay volume 500 μl. 
Binding was initiated by the addition of transfected human CB1 or CB2 CHO cell membranes (50 μg 
protein per well). All assays were performed at 37 °C for 60 min before termination by the addition 
of ice-cold Tris binding buffer, followed by vacuum filtration using a 24-well sampling manifold 
(Brandel Cell Harvester; Brandel Inc, Gaithersburg, MD, USA) and Brandel GF/B filters that had 
been soaked in wash buffer at 4°C for at least 24 h. Each reaction well was washed six times with a 
1.2 mL aliquot of Tris-binding buffer. The filters were oven-dried for 60 min and then placed in 3 
mL of scintillation fluid (Ultima Gold XR, PerkinElmer, Seer Green, Buckinghamshire, UK). 
Radioactivity was quantified by liquid scintillation spectrometry. Specific binding was defined as the 
difference between the binding that occurred in the presence and absence of 1 μM unlabelled 
CP55940. The concentration of [3H]CP55940 used in our displacement assays was 0.7 nM. The 
compounds used in this investigation were stored as stock solutions of 10 mM in DMSO, the vehicle 
concentration in all assay wells being 0.1% DMSO. Each point on each graph represents the mean of 
data obtained from six independent experiments. Each experiment was performed in duplicate for 
each concentration. 
[35S]GTPγS assay. The assay was carried out in the presence of [35S]GTPγS (0.1 nM), GDP (30 
µM), GTPγS (30 µM) and CHO cell membranes (1 mg/ml) overexpressing hCB1Rs or hCB2Rs. The 
assay buffer contained 50 mM Tris, 10 mM MgCl2, 100 mM NaCl, 0.2 mM EDTA and 1 mM DTT 
(dithiothreitol) at pH 7.4. Incubations were carried out at 30 °C for 90 min in a total volume of 500 
ml. The reaction was terminated by the addition of ice-cold wash buffer (50 mM Tris and 1 mg/ml 
BSA, pH 7.4) followed by rapid filtration under vacuum through Whatman GF/B glass-fibre filters 
(pre-soaked in wash buffer) 24-well sampling manifold (Brandel Cell Harvester; Brandel Inc, 
Gaithersburg, MD, USA) and Brandel GF/B filters that had been soaked in wash buffer at 4°C for at 
least 24 h. Each reaction well was washed six times with a 1.2 mL aliquot of Tris-binding buffer. The 
filters were oven-dried for 60 min and then placed in 3 mL of scintillation fluid (Ultima Gold XR, 
PerkinElmer, Seer Green, Buckinghamshire, UK). Bound radioactivity was determined by liquid 
scintillation counting. Basal binding of [35S]GTPγS was determined in the presence of 20 mM GDP 
and absence of cannabinoid. Non-specific binding was determined in the presence of 10 mM GTPgS. 
The compounds used in this investigation were stored as stock solutions of 10 mM in DMSO, the 
vehicle concentration in all assay wells being 0.1% DMSO. Each point on CB1R graph represents 
the mean of data obtained from six independent experiments. Each experiment was performed in 
duplicate for each concentration. This protocol was also used to obtain the data shown in the 2-AG 
and AEA CB2R graphs. Each point on the CP55940 CB2R graph represents the mean of data obtained 
from twelve independent experiments. Each experiment was performed in duplicate for each 
concentration. 
Dissociation kinetic assay. Dissociation kinetic assays were performed with [3H]CP55940 and 
Tris binding buffer (50 mM Tris–HCl, 50 mM Tris–base, 0.1% BSA, pH 7.4), total assay volume 500 
μl. Dissociation was initiated by addition of transfected human CB1 or CB2 CHO cell membranes (50 
μg protein per well). Dissociation times of 0.5 to 120 min at 25°C were used. To determine the 
nonspecific binding, experiments were also performed in the presence of a 1 μM concentration of the 
unlabeled ligand. All assays were performed at 37 °C for 60 min before termination by the addition 
of ice-cold Tris binding buffer, followed by vacuum filtration using a 24-well sampling manifold 
(Brandel Cell Harvester; Brandel Inc, Gaithersburg, MD, USA) and Brandel GF/B filters that had 
been soaked in wash buffer at 4°C for at least 24 h. Each reaction well was washed six times with a 
1.2 mL aliquot of Tris-binding buffer. The filters were oven-dried for 60 min and then placed in 3 
mL of scintillation fluid (Ultima Gold XR, PerkinElmer, Seer Green, Buckinghamshire, UK). 
Radioactivity was quantified by liquid scintillation spectrometry. Specific binding was defined as the 
difference between the binding that occurred in the presence and absence of 1 μM unlabelled 
CP55940. The concentration of [3H]CP55940 used in our displacement assays was 0.7 nM. The 
compounds used in this investigation were stored as stock solutions of 10 mM in DMSO, the vehicle 
concentration in all assay wells being 0.1% DMSO. Each point on the graph represents the mean of 
data obtained from four independent experiments. Each experiment was performed in duplicate for 
each concentration. 
Data analysis. Results were calculated as percentage changes from a basal level (zero) of 
[3H]CP55940 binding (in the presence of vehicle). GraphPad Prism 5.0 (GraphPad, San Diego, CA) 
was used to construct sigmoidal log concentration-response curves, and to calculate values of EC50, 
Emax, S.E.M and 95% confidence intervals. P values < 0.05 were considered to be significant.  
MAGL inhibition assay. Human recombinant MAGL and 4-NPA substrate were from Cayman 
Chemical. The enzymatic reaction was carried out at room temperature (final volume of 200 μL in 
10 mM Tris buffer, pH 7.2, containing 1 mM EDTA and 0.1 mg/ml BSA). A total of 150 μL of 4-
NPA 133.3 μM (final concentration = 100 μM) was added to 10 μL of DMSO containing the 
appropriate amount of compound and the reaction was initiated by the addition of 40 μL of MAGL 
(11 ng/well). After the reaction had proceeded for 30 min, absorbance values were then measured by 
using a Victor X3 Microplates Reader (PerkinElmer®) at 405 nm.1 The assay was generated in 96-
well microtiter plates. Two reactions were also run: one reaction containing no compounds and the 
second one containing neither inhibitor nor enzyme.  
Pharmacological in vivo study. Male CD-1 albino mice (Envigo, Varese, Italy) weighing 
approximately 22–25 g at the beginning of the experimental procedure, were used. Animals were 
housed in CeSAL (Centro Stabulazione Animali da Laboratorio, University of Florence) and used at 
least 1 week after their arrival. Ten mice were housed per cage (size 26 × 41 cm); animals were fed 
a standard laboratory diet and tap water ad libitum, and kept at 23 ± 1 °C with a 12 h light/dark cycle, 
light at 7 a.m. All animal manipulations were carried out according to the Directive 2010/63/EU of 
the European parliament and of the European Union council (22 September 2010) on the protection 
of animals used for scientific purposes. The ethical policy of the University of Florence complies 
with the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996; University of Florence assurance number: A5278-01). 
Formal approval to conduct the experiments described was obtained from the Animal Subjects 
Review Board of the University of Florence. Experiments involving animals have been reported 
according to ARRIVE guidelines.32 All efforts were made to minimize animal suffering and to reduce 
the number of animals used. 
Oxaliplatin-induced neuropathic pain model. Mice treated with oxaliplatin (2.4 mg kg-1) 
were  administered i.p. on days 1-2, 5-9, 12-14 (10 i.p. injections).27,33 Oxaliplatin was dissolved in 
5% glucose solution. Control animals received an equivalent volume of vehicle. Behavioral tests were 
performed on day 15. 
Cold plate test. The animals were placed in a stainless steel box (12 cm × 20 cm × 10 cm) with a 
cold plate as floor. The temperature of the cold plate was kept constant at 4 °C ± 1 °C. Pain-related 
behavior (licking of the hind paw) was observed and the time (seconds) of the first sign was recorded. 
The cut-off time of the latency of paw lifting or licking was set at 60 seconds. 
Compounds administration. C2 (1, 5, 10, 20 mg kg-1) was dissolved in 1% 
carboxymethylcellulose and orally administered. Measurements were performed 15, 30, 45, 60 and 
75 min after injection. Control mice were treated with vehicle. The MAGL inhibitor F (1 mg kg-1 
p.o.; Cayman Chemicals, USA) was dissolved in 1% carboxymethylcellulose and administered 15 
min after C2 (1-10 mg kg-1 p.o.). Measurements were performed 15, 30, 45, 60 and 75 min after C2 
injection. The selective CB1R (SR141716A; Tocris Bioscience, UK) and CB2R (SR144528; Tocris 
Bioscience, UK) antagonists were dissolved in saline solution with 5% DMSO and 5% Tween 20. 
Antagonists were administered i.p. 15 minutes before C2 (20 mg kg-1 p.o.). The dosages of 
SR141716A and SR144528 were according to previously published articles.34,35 
Statistical analysis. Behavioral measurements were performed on 16 mice for each treatment 
carried out in 2 different experimental sets (8 animals for single experimental session). Results were 
expressed as mean ± S.E.M. The analysis of variance of behavioral data was performed by one way 
ANOVA, a Bonferroni's significant difference procedure was used as post-hoc comparison. P values 
of less than 0.05 or 0.01 were considered significant. Investigators were blind to all experimental 
procedures. Data were analysed using the “Origin 9” software (OriginLab, Northampton, USA). 
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